We are very pleased to welcome Reiko Namikawa, M.D., Ph.D., to the REGiMMUNE leadership team as Vice President of Strategic Development Planning. Dr. Namikawa’s more than 25 years of research, clinical and business experience in life sciences complements the significant expertise already on board at the company. At REGiMMUNE, Dr. Namikawa will be applying her medical and clinical research and development background to the design and implementation of the company’s preclinical studies. Additionally, she will contribute her business experience to help the company achieve its business development objectives for product licensing and collaborations.

Among her many accomplishments, Dr. Namikawa was a founding scientist at SyStemix, Inc. where she developed the SCID-hu mouse system for the company, which she invented at Stanford University with her colleagues Hideto Kaneshima and Mike McCune. Her business experience in the biotechnology industry encompasses strategic business planning, business development, and analysis for product commercialization as well as in- and out-licensing activities between U.S. and Japanese pharmaceutical companies.

Dr. Namikawa received both her Ph.D. and M.D. degrees from Nagoya University School of Medicine; and was a postdoctoral fellow under in Dr. Irving Weissman at Stanford University. Her research focus was in the disease mechanisms of hematology, oncology, immunology, and infectious diseases. She is the author of more than 60 publications in major journals and 5 issued patents.

US MEDIA CONTACT:
Debra Bannister
530 676-8001
email contact